文献速递角膜与眼表疾病

美国圆锥角膜患者角膜交联治疗可及性与利用的挑战

Challenges to the Access and Utilization of Corneal Cross-Linking in Patients With Keratoconus in the United States.
PubMed 文献 · Am J Ophthalmol · 2026-07-29

本文为视角文章,探讨美国圆锥角膜患者接受角膜交联(CXL)治疗的可及性差异。目前仅有一种FDA批准的 epithelium-off CXL 方案(KXL系统使用Photrexa或Photrexa Viscous),其可及性受高成本、保险覆盖和专有方案限制。2025年FDA批准 epithelium-on 疗法Epioxa,但其批发采购成本为78,500美元,且Photrexa将于2026年逐步淘汰,可能加剧可及性差异。作者建议暂停Photrexa淘汰并成立跨学科工作组制定可及性框架。

要点

  • CXL已被证明可延缓圆锥角膜进展并减少角膜移植需求。
  • 美国仅有一种FDA批准的 epithelium-off CXL方案,可及性受高成本和保险限制。
  • Epioxa于2025年获FDA批准,批发采购成本78,500美元,疗效与Photrexa可比性尚不确定。

核心结论

  • Epioxa获批和Photrexa计划淘汰可能加剧美国圆锥角膜患者CXL治疗可及性差异。
  • 建议暂停Photrexa淘汰直至制定正式CXL可及性计划并充分证明Epioxa长期疗效。

研究设计与样本

  • 本文为视角文章,基于作者护理圆锥角膜患者的经验、美国CXL历史总结和文献综述。

主要发现

  • 美国目前仅有一种FDA批准的 epithelium-off CXL方案(KXL系统使用Photrexa或Photrexa Viscous)。
  • CXL可及性受高成本、保险覆盖和专有方案限制,导致服务不足患者治疗机会减少。
  • Epioxa于2025年获FDA批准为 orphan drug designation 的 epithelium-on CXL疗法。
  • Epioxa批发采购成本为78,500美元,其短期和长期视力及最大角膜曲率效果与Photrexa的可比性不确定。
  • Photrexa将于2026年逐步淘汰,届时美国将不再有FDA批准的 epithelium-off CXL疗法。

关键数值与推荐

  • FDA批准的 epithelium-off CXL方案为KXL系统使用Photrexa或Photrexa Viscous。
  • Epioxa为 epithelium-on CXL疗法,2025年获FDA批准,批发采购成本78,500美元。
  • Photrexa计划于2026年逐步淘汰。

临床怎么用

  • 临床医生应关注CXL治疗可及性差异,为患者倡导可负担的治疗选择。
  • 考虑成立跨学科工作组制定CXL治疗可及性框架。
  • 在Epioxa长期疗效充分证明前,建议暂停Photrexa淘汰。

局限性

  • 本文为视角文章,非系统研究,基于作者经验和文献综述。
  • 未提供具体样本量、P值或定量比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE OR PURPOSE: To investigate current disparities in access to corneal cross-linking (CXL) for patients with keratoconus in the United States and to anticipate further disparities in the wake of Epioxa approval and planned Photrexa phasing out. DESIGN: Perspective essay. METHODS, INTERVENTION, OR TESTING: This essay reflects on experiences from all authors in their care for patients with keratoconus, a historical summary of CXL in the United States, and a literature review. RESULTS: CXL has been proven to slow the progression of keratoconus and reduce the need for corneal transplants. Currently, there is only 1 Food and Drug Administration (FDA)-approved epithelium-off CXL protocol in the United States (KXL system using Photrexa or Photrexa Viscous), and its access has been limited by high costs, insurance coverage, and proprietary protocols. The result is that underserved patients have had reduced access to treatment. In 2025, the FDA approved Epioxa, an epithelium-on CXL therapy, under an orphan drug designation. In addition to concerns surrounding affordability, it is uncertain whether Epioxa has comparable short- and long-term effectiveness to Photrexa in terms of visual acuity and maximum keratometry. With Epioxa's recently reported wholesale acquisition cost of $78,500, the authors feel the need to advocate for patients who will be unable to receive these potentially vision-saving therapies. Further concerning is that Photrexa will be phased out in 2026, meaning there will no longer be an FDA-approved epithelium-off CXL therapy available in the United States. CONCLUSIONS: With the approval of Epioxa and the planned phasing out of Photrexa, we underscore the risk of exacerbating disparities in access to CXL and propose the formation of an interdisciplinary task force aimed at developing an access framework for CXL therapy for all patients. We believe that the first step is to pause the phasing out of Photrexa until (1) there is a formalized plan in place to combat the issues of CXL access as detailed here and (2) the long-term efficacy of Epioxa can be sufficiently demonstrated.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jo JJ, Bian Y, Chamberlain WD, et al. Challenges to the Access and Utilization of Corneal Cross-Linking in Patients With Keratoconus in the United States. Am J Ophthalmol. 2026. PMID: 42526732. doi:10.1016/j.ajo.2026.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。